Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | LOX | P28300 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 2/20 | 0.31 |
| ▸ | SELL | P14151 | 1/20 | 0.31 |
| ▸ | SELP | P16109 | 1/20 | 0.31 |
| ▸ | SELE | P16581 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23235858 | 0.85 | GRM5 (0.32) | GRM5 | |
| SCHEMBL1478000 | 0.84 | LOX (0.35) | LOX | |
| SCHEMBL12788161 | 0.80 | CYP1A1 (0.33) | LOX | |
| SCHEMBL9956785 | 0.79 | GRM5 (0.50) | GRM5 | |
| SCHEMBL3721314 | 0.78 | POLB (0.32) | ALDH1A1LOXGRM5 | |
| SCHEMBL3691802 | 0.78 | FFAR1 (0.45) | FFAR1ALDH1A1TSHRGRM5SELL | |
| SCHEMBL31349195 | 0.78 | GRM5 (0.56) | FFAR1GRM5ACHE | |
| SCHEMBL3347354 | 0.78 | GRM5 (0.56) | FFAR1GRM5ACHE | |
| SCHEMBL440124 | 0.75 | GRM5 (0.50) | FFAR1ALDH1A1GRM5ACHE | |
| SCHEMBL19677742 | 0.75 | HDAC1 (0.31) | LOXGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111961052-B | Preparation method of gamma-carboline derivative | 沈阳师范大学 | 2022-06-03 | — | — | CN | disclosed |
| US-11345665-B2 | Chiral 1,3-diarylimidazolium salt carbene precursor, synthesis method therefor, metal salt compound and application thereof | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2022-05-31 | — | — | US | disclosed |
| US-20200369620-A1 | CHIRAL 1,3-DIARYLIMIDAZOLIUM SALT CARBENE PRECURSOR, SYNTHESIS METHOD THEREFOR, METAL SALT COMPOUND AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2020-11-26 | — | — | US | disclosed |
| CN-111961052-A | Preparation method of gamma-carboline derivative | 沈阳师范大学 | 2020-11-20 | — | — | CN | disclosed |
| EP-3712132-A1 | CHIRAL 1,3-DIARYLIMIDAZOLIUM SALT CARBENE PRECURSOR, SYNTHESIS METHOD THEREFOR, METAL SALT COMPOUND AND APPLICATION THEREOF | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2020-09-23 | — | — | EP | disclosed |
| US-9309463-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-04-12 | — | — | US | disclosed |
| US-20140077131-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2014-03-20 | — | — | US | disclosed |
| EP-1149067-B1 | 7-ARYL-6(Z)HEPTATRIENOIC ACID RETINAMIDES AS APOPTOSIS INDUCING COMPOUNDS AND THEIR USE AS ANTI-CANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2004-02-25 | — | — | EP | disclosed |
| EP-1149067-A1 | 7-ARYL-6(Z)HEPTATRIENOIC ACID RETINAMIDES AS APOPTOSIS INDUCING COMPOUNDS AND THEIR USE AS ANTI-CANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-31 | — | — | EP | disclosed |
| US-6310247-B1 | HAS APOPTOTIC ACTIVITY USEFUL FOR PROPHYLAXIS AND THERAPY OF CANCER | HOFFMANN-LA ROCHE INC. | 2001-10-30 | — | — | US | disclosed |
| WO-2000035856-A1 | 7-ARYL-6(Z)HEPTATRIENOIC ACID RETINAMIDES AS APOPTOSIS INDUCING COMPOUNDS AND THEIR USE AS ANTI-CANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369620-A1 | CHIRAL 1,3-DIARYLIMIDAZOLIUM SALT CARBENE PRECURSOR, SYNTHESIS METHOD THEREFOR, METAL SALT COMPOUND AND APPLICATION THEREOF | CYP51A1, SLC39A11, ZC3HAV1L | FFAR1 1296/4885ALDH1A1 777/4885TSHR 4702/4885 |
| US-11345665-B2 | Chiral 1,3-diarylimidazolium salt carbene precursor, synthesis method therefor, metal salt compound and application thereof | CYP51A1, SLC39A11, ZC3HAV1L | FFAR1 1296/4885ALDH1A1 777/4885TSHR 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.